Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Uncombable hair and Sparse eyebrow; and common findings: Sparse body hair. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 1 | Alopecia |
Age of onset: at birth.
HRURF encodes HR upstream open reading frame (34 aa). May function as an inhibitory translational control element that can negatively regulate protein translation of HR gene
Hypotrichosis 4 is associated with mutations in the HRURF gene on chromosome 8.
HRURF is classified as a druggable target with score 0.0.
Genetic testing for HRURF is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypotrichosis 4 has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 1 common feature.
No clinical trials have been registered for hypotrichosis 4.
35 publications have been identified in PubMed for hypotrichosis 4. Research spans Epidemiology / Natural History (23%), Review / Meta-Analysis (20%), and Case Report / Case Series (14%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 8 | 23% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:49 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
7 |
20% |
Patient case studies | 5 | 14% |
Laboratory research | 5 | 14% |
Clinical study results | 4 | 11% |
New treatment approaches | 4 | 11% |
Other research | 1 | 3% |
Testing and diagnosis research | 1 | 3% |
Xu P (2026). [PMID: 42258011](https://pubmed.ncbi.nlm.nih.gov/42258011/). *World J Urol*. [Epidemiology / Natural History]
Kim YN (2026). [PMID: 41761855](https://pubmed.ncbi.nlm.nih.gov/41761855/). *ChemistryOpen*. [Basic Science / Preclinical]
Li T (2026). [PMID: 41611183](https://pubmed.ncbi.nlm.nih.gov/41611183/). *J Ethnopharmacol*. [Basic Science / Preclinical]
Zorlu Ö (2026). [PMID: 41915583](https://pubmed.ncbi.nlm.nih.gov/41915583/). *Acta Dermatovenerol Alp Pannonica Adriat*. [Epidemiology / Natural History]
Fu M (2026). [PMID: 41578511](https://pubmed.ncbi.nlm.nih.gov/41578511/). *Medicine (Baltimore)*. [Case Report / Case Series]
AlHashem A (2026). [PMID: 41474134](https://pubmed.ncbi.nlm.nih.gov/41474134/). *Am J Med Genet A*. [Case Report / Case Series]
van Hensbergen I (2026). [PMID: 41705568](https://pubmed.ncbi.nlm.nih.gov/41705568/). *Vet Dermatol*. [Basic Science / Preclinical]
Argobi Y (2026). [PMID: 41914454](https://pubmed.ncbi.nlm.nih.gov/41914454/). *J Cosmet Dermatol*. [Epidemiology / Natural History]
Keller-Rosenthal N (2026). [PMID: 41242654](https://pubmed.ncbi.nlm.nih.gov/41242654/). *J Invest Dermatol*. [Basic Science / Preclinical]
Xi L (2025). [PMID: 41096925](https://pubmed.ncbi.nlm.nih.gov/41096925/). *Int J Mol Sci*. [Review / Meta-Analysis]